The outcomes of our patient specimen data analysis and mechanistic study of LUSC cell lines provide reinforcing lines of evidence to support that copy number amplification of SLITRK3 is not a random passenger aberration in the LUSC tumor genome but has a role in activating NTRK3 and thereby promoting CSCs. This evidence concerns the gene SLITRK3 and neoplasm.